Q4 2025 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) has strategically focused its resources on ChemPass AI, a computational generative AI engine, to enhance drug development and agricultural chemicals.
- The company has successfully reduced its operating expenses from $22 million in 2024 to approximately $13.8 million in 2025, reflecting effective cost management.
- Evogene Ltd (EVGN) has entered into a second collaboration with Google Cloud, integrating advanced AI agents to improve the probability of development success for novel small molecule candidates.
- The company has established multiple partnerships in human health and agriculture, including collaborations with Bayer and Corteva, indicating strong industry relationships.
- Evogene Ltd (EVGN) has streamlined its operations by divesting non-core activities and resizing its organization, which is expected to sustain reduced expense levels in future periods.
- Evogene Ltd (EVGN) experienced a decrease in revenues for 2025, totaling approximately $3.9 million compared to $5.6 million in 2024, primarily due to lower revenue from AgPlenus' activities.
- The company recorded an impairment of approximately $2.2 million related to Casterra's seed inventory, impacting the cost of revenues.
- Net loss for 2025 was approximately $7.8 million, despite a decrease from the previous year, indicating ongoing financial challenges.
- The decrease in financing income net from $4 million in 2024 to $0.6 million in 2025 reflects reduced financial gains from prefunded warrants and fundraising activities.
- Evogene Ltd (EVGN) faced a significant decline in demand for castor seeds, leading to the cessation of Casterra AG's operations in Kenya and a focus shift to the Brazilian market.
Welcome to Evogene's fourth-quarter 2025 results conference call. (Operator Instructions) As a reminder, this conference is being recorded, March 5, 2026.
Before we begin, I would like to caution that certain statements made during this earnings conference call by Evogene's management will constitute forward-looking statements that relate to future events. This presentation contains forward-looking statements relating to future events and Evogene, Ltd., the company, may from time to time make other statements regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995, the PSLRA, and other securities laws as amended. Statements that are not statements of historical fact may be deemed forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should, plan, estimate, intend, and potential or words of similar meaning. We are using forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
